The FDA promises to streamline the dauntingly complex rules for approving nicotine products

The FDA announced it will reevaluate and simplify its regulatory approach to approving nicotine products such as vapes and flavored nicotine pouches, aiming to "smooth the way" for products to legally enter the market by changing rules to speed up the authorization process. This comes after years of regulatory bottlenecks, burdensome requirements, and long delays that have made it extremely difficult for manufacturers to obtain premarket approval.

The need for reform is underscored by a lawsuit filed by Helix Innovations (an Altria subsidiary) and NJOY, along with Texas retailers, arguing the FDA has failed to comply with the Family Smoking Prevention and Tobacco Control Act's (TCA) 180-day deadline for reviewing applications. The 2021 final rule created an unmanageable backlog of approximately 4.8 million product applications, with the FDA reviewing only 0.6% by January 2021 and still facing about 130,000 applications by March 2025. The FDA's three-phase review process—acceptance, filing, and substantive review—repeatedly exceeded statutory deadlines and demanded information far beyond TCA requirements, including "granular descriptions of product formulation" with little relevance to public health concerns.

A Department of Health and Human Services (HHS) spokesperson stated the Trump administration is committed to keeping nicotine away from children while providing safer alternatives for adults seeking to quit smoking. Legal expert Azim Chowdhury noted that current premarket application requirements involve "a tremendous amount of potential redundancy" and can cost businesses "millions or even tens of millions of dollars," creating a system navigable mainly by large tobacco companies and multinational corporations. He emphasized that a regulated marketplace must realistically reflect what adult consumers actually want to successfully move people away from combustible cigarettes.

(Source：Reason Magazine)